## Supplementary table S1: additional treatment with avastin stratified by (a) TCGA subtype and (b) EGFR amplification status

a

Classical	Mesenchymal	Proneural	p Value
n (%)	n (%)	n (%)	
Numb	er of treatment pre b	evacizumab	
1 (5%)	1 (5%)	0 (0%)	0.453
5 (26%)	5 (24%)	5 (22%)	
7 (37%)	9 (43%)	10 (43%)	
4 (21%)	6 (29%)	3 (13%)	
2 (11%)	0 (0%)	5 (22%)	
Number	of treatment during	<u>bevacizumab</u>	
11 (58%)	9 (43%)	9 (39%)	0.588
5 (26%)	10 (48%)	10 (43%)	
2 (11%)	2 (10%)	4 (17%)	
1 (5%)	0 (0%)	0 (0%)	
Number	er of treatment post b	<u> </u> pevacizumab	
10 (53%)	13 (62%)	17 (74%)	0.133
5 (26%)	7 (33%)	3 (13%)	
4 (21%)	0 (0%)	1 (4%)	
0 (0%)	1 (5%)	1 (4%)	
0 (0%)	0 (0%)	1 (4%)	
	n (%)   Number   1 (5%)   5 (26%)   7 (37%)   4 (21%)   2 (11%)   Number   11 (58%)   5 (26%)   2 (11%)   1 (5%)   Number   10 (53%)   5 (26%)   4 (21%)   0 (0%)	n (%)   n (%)   Number of treatment pre b   1 (5%)   1 (5%)   5 (26%)   5 (24%)   7 (37%)   9 (43%)   4 (21%)   6 (29%)   2 (11%)   0 (0%)   Number of treatment during   11 (58%)   9 (43%)   5 (26%)   10 (48%)   2 (11%)   2 (10%)   1 (5%)   0 (0%)   Number of treatment post b   10 (53%)   13 (62%)   5 (26%)   7 (33%)   4 (21%)   0 (0%)   1 (5%)   1 (	n (%)   n (%)   n (%)

	EGFR amplification status						
	No	Yes	Unknown	p value			
	Numb	er of treatment pro	e bevacizumab				
0	0 (0%)	2 (9%)	0 (0%)	0,298			
1	8 (30%)	6 (26%)	1 (8%)				
2	10 (37%)	7 (30%)	9 (69%)				
3	5 (19%)	5 (22%)	3 (23%)				
4	4 (15%)	3 (13%)	0 (0%)				
	<u>Number</u>	of treatment duri	ng bevacizumab				
0	11 (41%)	11 (48%)	7 (54%)	0,785			
1	13 (48%)	7 (30%)	5 (38%)				
2	3 (11%)	4 (17%)	1 (8%)				
3	0 (0%)	1 (4%)	0 (0%)				
	Numbe	er of treatment pos	t bevacizumab				
0	20 (74%)	15 (65%)	5 (38%)	0,109			
1	5 (19%)	5 (22%)	5 (38%)				
2	1 (4%)	3 (13%)	1 (8%)				
3	0 (0%)	0 (0%)	2 (15%)				
4	1 (4%)	0 (0%)	0 (0%)				